Comparative pharmacokinetics of PAMAM-OH dendrimers and HPMA copolymers in ovarian tumor-bearing mice

Drug Delivery and Translational Research

Volumn 3, Issue 3, 2013, Pages 260-271

  Sadekar, S ^a   Linares, O ^b   Noh, G J ^d   Hubbard, D ^a,c   Ray, A ^a   Janat Amsbury M ^a,b   Peterson, C M ^a,b   Facelli, J ^a,b   Ghandehari, H ^a,c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c University of Utah   (United States)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Compartmental pharmacokinetics; N (2 hydroxypropyl)methacrylamide (HPMA) copolymer; Poly(amido amine) (PAMAM) dendrimer; Polymer architecture

Indexed keywords

COPOLYMER; POLY(N (2 HYDROXYPROPYL)METHACRYLAMIDE; POLYAMIDOAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; HYDRODYNAMICS; IN VIVO STUDY; KIDNEY CLEARANCE; KINETICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; URINE;

EID: 84877836589     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0119-6     Document Type: Article

References (40)

1. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5): 347-60.
2. Qiu LY, Bae YH. Polymer architecture and drug delivery. Pharm Res. 2006;23(1): 1-30.
3. Esfand R, Tomalia DA. Poly (amidoamine)(PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today. 2001;6(8): 427-36.
4. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. A new class of polymers: starburst-dendritic macromolecules. Polym J. 1985;17(1): 117-32.
5. Tomalia D, Reyna L, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans. 2007;35: 61-7.
6. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev. 2005;57(15): 2215-37.
7. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000;65(1-2): 133-48.
8. Wijagkanalan W, Kawakami S, Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm Res. 2011;28(7): 1500-19.
9. Duncan R. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. Adv Drug Deliv Rev. 2009;61(13): 1131-48.
10. Kopecek J, Kopecková P. HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev. 2010;62(2): 122-49.
11. Borgman M, Coleman T, Kolhatkar R, Geyser-Stoops S, Line B, Ghandehari H. Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A″-DTPA) conjugates show increased kidney accumulation. J Control Release. 2008;132(3): 193-9.
12. Konak C, Rathi RC, Kopeckova P, Kopecek J. Effect of side-chains on solution properties of N-(2-hydroxypropyl) methacrylamide copolymers in aqueous solvents. Polymer. 1993;34(22): 4767-73.
13. Lammers T, Kuhnlein R, Kissel M, Subr V, Etrych T, Pola R, et al. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release. 2005;110(1): 103-18.
14. Chen B, Jerger K, Fréchet JMJ, Szoka Jr FC. The influence of polymer topology on pharmacokinetics: differences between cyclic and linear PEGylated poly (acrylic acid) comb polymers. J Control Release. 2009;140(3): 203-9.
15. Fox ME, Szoka FC, Fre chet JMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res. 2009;42(8): 1141-51.
16. Nasongkla N, Chen B, Macaraeg N, Fox ME, Fréchet JMJ, Szoka FC. Dependence of pharmacokinetics and biodistribution on polymer architecture: effect of cyclic versus linear polymers. J Am Chem Soc. 2009;131(11): 3842-3.
17. Sadekar S, Ray A, Janat-Amsbury M, Peterson C, Ghandehari H. Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice. Biomacromolecules. 2011;12(1): 88-96.
18. Cutnell JJ, Kenneth. Physics. fourth ed: Wiley; 1998. p. 308.
19. Rippe C, Asgeirsson D, Venturoli D, Rippe A, Rippe B. Effects of glomerular filtration rate on Ficoll sieving coefficients (theta) in rats. Kidney Int. 2006;69(8): 1326-32.
20. Tande B, Wagner N, Mackay M, Hawker C, Jeong M. Viscosimetric, hydrodynamic, and conformational properties of dendrimers and dendrons. Macromolecules. 2001;34(24): 8580-5.
21. Ulbrich K, Subr V. Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev. 2010;62(2): 150-66.
22. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10): 2861-71.
23. Deen W, Bohrer M, Epstein N. Effects of molecular size and configuration on diffusion in microporous membranes. AICHE J. 1981;27(6): 952-9.
24. Nishikawa M, Takakura Y, Hashida M. Pharmacokinetic evaluation of polymeric carriers. Adv Drug Deliv Rev. 1996;21(2): 135-55.
25. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2): 271-84.
26. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol. 2011;2: 281-98.
27. Gillies ER, Dy E, Fréchet JMJ, Szoka FC. Biological evaluation of polyester dendrimer: poly (ethylene oxide)"bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharm. 2005;2(2): 129-38.
28. Lim J, Guo Y, Rostollan CL, Stanfield J, Hsieh JT, Sun X, et al. The role of the size and number of polyethylene glycol chains in the biodistribution and tumor localization of triazine dendrimers. Mol Pharm. 2008;5(4): 540-7.
29. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987;47(12): 3039.
30. Ohlson M, Sörensson J, Lindström K, Blom AM, Fries E, Haraldsson B. Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol-Renal. 2001;281(1): F103.
31. Venturoli D, Rippe B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol-Renal. 2005;288(4): F605.
32. Pluen A, Netti PA, Jain RK, Berk DA. Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations. Biophys J. 1999;77(1): 542-52.
33. Gennes PG. Reptation of a polymer chain in the presence of fixed obstacles. J Chem Phys. 1971;55(2): 572-9.
34. Deen WM, Bohrer MP, Brenner BM. Macromolecule transport across glomerular capillaries: application of pore theory. Kidney Int. 1979;16(3): 353-65.
35. Kobayashi H, Kawamoto S, Jo SK, Sato N, Saga T, Hiraga A, et al. Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent. Kidney Int. 2002;61(6): 1980-5.
36. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98(5): 335-44.
37. Uzgiris E. The role of molecular conformation on tumor uptake of polymeric contrast agents. Invest Radiol. 2004;39(3): 131-7.
38. Uzgiris E, Cline H, Moasser B, Grimmond B, Amaratunga M, Smith JF, et al. Conformation and structure of polymeric contrast agents for medical imaging. Biomacromolecules. 2004;5(1): 54-61.
39. Uzgiris E. A cell-surface polymer reptation mechanism for tumor transendothelial transport of macromolecules. Technol Cancer Res T. 2008;7(3): 257-68.
40. Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med. 2009;7(1): 51.